Alector, Inc.
ALEC Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$1.83
KIRA · Stoqly’s AI analyst, in plain words
- Alector, Inc. had $21.0M of revenue in fiscal 2025, down 79.1% on the year before. Over five years, revenue changed −0.1% a year on average.
- Its operating margin was −741.3%, down 597.1 pts: of every 100 in sales, about −741 is left after running the business.
- Alector, Inc. lost $143M in fiscal 2025.
- Free cash flow was −$184M in fiscal 2025, −874.7% of revenue.
- Alector, Inc. has $246M more cash than debt.
Market cap
$204M
P/E
—
Revenue
$21.0M
Net income
−$143M
Free cash flow
−$184M
Operating margin
−741.3%
Alector, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−79.1%
No. Sales fell 79.1% last year.
Does it make a profit?
−679.2%
No. It lost money last year.
Does profit turn into cash?
−874.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alector, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Alector, Inc.
- CIK
- 0001653087
Alector, Inc. · ALEC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $207M | $134M | $97.1M | $101M | $21.0M |
| Revenue growth | 881.5% | −35.5% | −27.3% | 3.6% | −79.1% |
| Operating margin | −18.0% | −103.2% | −156.3% | −144.2% | −741.3% |
| Net income | −$36.3M | −$133M | −$130M | −$119M | −$143M |
| Net margin | −17.5% | −99.8% | −134.3% | −118.4% | −679.2% |
| Diluted EPS | −$0.45 | −$1.62 | −$1.56 | −$1.23 | −$1.39 |
| Cash | |||||
| Cash from operations | $299M | −$20.3M | −$184M | −$230M | −$184M |
| Capital expenditure | $3.2M | $4.1M | $2.4M | $1.3M | $0.0M |
| Free cash flow | $295M | −$24.4M | −$187M | −$231M | −$184M |
| FCF margin | 142.6% | −18.3% | −192.1% | −229.9% | −874.7% |
| Share count change | 3.4% | 2.6% | 1.5% | 15.4% | 6.6% |
| Debt and strength | |||||
| Cash and short-term investments | $735M | $713M | $549M | $413M | $256M |
| Debt incl. finance leases | — | — | $0.0M | $10.0M | $10.4M |
| Shareholders' equity | $301M | $214M | $134M | $127M | $30.6M |
| Current ratio | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| Returns and quality | |||||
| Return on equity | −12.8% | −51.8% | −74.8% | −91.2% | −181.6% |
| Return on tangible equity | −12.1% | −62.2% | −97.2% | −93.9% | −466.3% |
| Piotroski F-score | 4 | 2 | 0 | 2 | 1 |
| Altman Z'' | 3.4 | 2.1 | −1.0 | −3.3 | −9.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
4 insiders
Of sales under plans
5%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alector, Inc. · ALEC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.83 a share, the company is worth $204M.
Source: SEC EDGAR XBRL filings (CIK 0001653087). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.